Use of maintenance therapy and incidence of recurrent Cytomegalovirus DNAemia among allogeneic hematopoietic cell transplant recipients
José F. Camargo(University of Miami), Michele I. Morris(University of Miami), Erik L. Kimble(University of Washington), Krishna V. Komanduri(University of Miami), Anthony D. Anderson(Sylvester Comprehensive Cancer Center), Rossana Rosa(Jackson Memorial Hospital)
Cited by 10
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Assessment of Cytomegalovirus-Specific Cell-Mediated Immunity for the Prediction of Cytomegalovirus Disease in High-Risk Solid-Organ Transplant Recipients: A Multicenter Cohort Study
|Clinical Infectious Diseases|2012|299